IGHG3 and neoplasm: By using the B16-F10 lung metastasis model and a prophylactic treatment with TA99 antibody of different IgG subclasses (targeting Trp1 expressed on B16-F10 cells), the authors showed in that study that IgG2a offers superior tumor control to IgG1, IgG2b, and IgG3 (8).